BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 22437221)

  • 1. Tolerability of concomitant use of selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors and oxymorphone extended release.
    Peniston JH; Hu X; Potts SL; Wieman MS; Turk DC
    Postgrad Med; 2012 Mar; 124(2):114-22. PubMed ID: 22437221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting acceptability of titrated oxymorphone extended release in chronic low back pain - an individual patient analysis.
    Peniston JH; Xiang Q; Gould EM
    Curr Med Res Opin; 2010 Aug; 26(8):1861-71. PubMed ID: 20521870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
    Peniston JH; Gould E
    Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain.
    Katz N; Rauck R; Ahdieh H; Ma T; Gerritsen van der Hoop R; Kerwin R; Podolsky G
    Curr Med Res Opin; 2007 Jan; 23(1):117-28. PubMed ID: 17257473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
    Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
    Cochrane Database Syst Rev; 2015 May; 2015(5):CD011681. PubMed ID: 25931277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A; Ma C; Ahdieh H; Galer BS
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study.
    Hale ME; Ahdieh H; Ma T; Rauck R;
    J Pain; 2007 Feb; 8(2):175-84. PubMed ID: 17145204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults.
    Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
    Cochrane Database Syst Rev; 2015 Apr; 4(4):CD002919. PubMed ID: 25829028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.
    Hale ME; Dvergsten C; Gimbel J
    J Pain; 2005 Jan; 6(1):21-8. PubMed ID: 15629415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer.
    Slatkin NE; Rhiner MI; Gould EM; Ma T; Ahdieh H
    J Opioid Manag; 2010; 6(3):181-91. PubMed ID: 20642247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
    Aqua K; Gimbel JS; Singla N; Ma T; Ahdieh H; Kerwin R
    Clin Ther; 2007 Jun; 29(6):1000-12. PubMed ID: 17692717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials.
    Machado M; Einarson TR
    J Clin Pharm Ther; 2010 Apr; 35(2):177-88. PubMed ID: 20456736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.
    Welsch P; Üçeyler N; Klose P; Walitt B; Häuser W
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD010292. PubMed ID: 29489029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trajectory and magnitude of response in adults with anxiety disorders: a Bayesian hierarchical modeling meta-analysis of selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and benzodiazepines.
    Mendez EM; Mills JA; Suresh V; Stimpfl JN; Strawn JR
    CNS Spectr; 2024 Jun; 29(3):187-196. PubMed ID: 38523533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials.
    Machado M; Iskedjian M; Ruiz I; Einarson TR
    Curr Med Res Opin; 2006 Sep; 22(9):1825-37. PubMed ID: 16968586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors as adjuncts for postoperative pain management: systematic review and meta-analysis of randomised controlled trials.
    Wang L; Tobe J; Au E; Tran C; Jomy J; Oparin Y; Couban RJ; Paul J
    Br J Anaesth; 2022 Jan; 128(1):118-134. PubMed ID: 34756632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
    Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC
    Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Titration with oxymorphone extended release to achieve effective long-term pain relief and improve tolerability in opioid-naive patients with moderate to severe pain.
    Rauck R; Ma T; Kerwin R; Ahdieh H
    Pain Med; 2008 Oct; 9(7):777-85. PubMed ID: 18950436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 3, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of Xtampza ER in patients with moderate-to-severe chronic low back pain.
    Katz N; Kopecky EA; O'Connor M; Brown RH; Fleming AB
    Pain; 2015 Dec; 156(12):2458-2467. PubMed ID: 26262828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study.
    McIlwain H; Ahdieh H
    Am J Ther; 2005; 12(2):106-12. PubMed ID: 15767827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.